Lantern Pharma Inc. ( NASDAQ: LTRN) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Panna Sharma - President & CEO David Margrave - CFO ...

Lantern's proprietary RADR ® platform has grown during Q1 2025 to approximately 200 billion oncology-focused data points across multiple sources (proprietary, collaborative and public) of oncology, ...

Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm ...

Q1 2025 Earnings Call Transcript May 12, 2025 Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.83, ...

UK life sciences investor Syncona is bankrolling a new gene therapy company, Beacon Therapeutics, that emerged this morning with a pipeline ... through to value inflection points.” ...

However, much remains to be resolved before a true inflection point can be called ... research that answers these questions, and creates therapeutics as a consequence, will need substantial ...

MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the ... from an operational and financial standpoint to drive our clinical pipeline to key inflection points and remain on track to ...

BOSTON , May 14, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today reported pipeline updates and ...

ZyVersa Therapeutics, Inc. has announced several key milestones regarding its drug development pipeline, expecting to begin a Phase 2a clinical trial for its Cholesterol Efflux Mediator™ VAR 200 ...